• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    US HIV Diagnostics Market

    ID: MRFR/Pharma/15130-HCR
    100 Pages
    Garvit Vyas
    October 2025

    US HIV Diagnostics Market Research Report By Test Type (Antibody Tests, Antigen Tests, Nucleic Acid Tests), By End User (Hospitals, Diagnostic Laboratories, Home Care Settings), By Product Type (Tests Kits, Instruments, Software) and By Technology (Elisa, Rapid Testing, Polymerase Chain Reaction) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US HIV Diagnostics Market Infographic
    Purchase Options

    US HIV Diagnostics Market Summary

    As per MRFR analysis, the US HIV Diagnostics Market Size was estimated at 690.48 USD Million in 2024. The US HIV Diagnostics Market is projected to grow from 718.44 USD Million in 2025 to 1068.59 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 4.05% during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The US HIV Diagnostics Market is experiencing robust growth driven by technological advancements and increasing awareness.

    • Technological advancements in testing are enhancing the accuracy and speed of HIV diagnostics.
    • The largest segment in the market is molecular diagnostics, which is witnessing significant adoption due to its precision.
    • Home testing kits are emerging as the fastest-growing segment, reflecting a shift towards more accessible testing options.
    • Rising prevalence of HIV and government initiatives are key drivers propelling market expansion.

    Market Size & Forecast

    2024 Market Size 690.48 (USD Million)
    2035 Market Size 1068.59 (USD Million)

    Major Players

    Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Becton Dickinson and Company (US), Hologic Inc. (US), Cepheid (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US)

    US HIV Diagnostics Market Trends

    The HIV Diagnostics Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing emphasis on early detection. Innovations in testing methods, such as rapid tests and self-testing kits, are becoming more prevalent, allowing for quicker results and greater accessibility. This shift is particularly relevant in the context of public health initiatives aimed at reducing transmission rates and improving patient outcomes. Furthermore, the integration of digital health solutions is enhancing the efficiency of testing processes, enabling healthcare providers to reach underserved populations more effectively. In addition to technological advancements, there is a growing awareness of the importance of regular testing among at-risk populations. Educational campaigns and community outreach programs are fostering a culture of proactive health management. This trend is likely to continue, as stakeholders recognize the critical role of early diagnosis in controlling the spread of HIV. Overall, the hiv diagnostics market appears poised for growth, with a focus on innovation and accessibility shaping its future landscape.

    Technological Advancements in Testing

    Recent innovations in testing technologies are revolutionizing the hiv diagnostics market. Rapid tests and self-testing kits are gaining traction, providing individuals with the ability to receive results quickly and conveniently. These advancements not only enhance accessibility but also contribute to timely diagnosis and treatment, which are essential for effective disease management.

    Increased Awareness and Education

    There is a notable rise in awareness regarding the importance of regular testing for HIV. Educational initiatives and community outreach programs are playing a crucial role in informing at-risk populations about the benefits of early detection. This trend is fostering a proactive approach to health management, which is vital for controlling the spread of the virus.

    Integration of Digital Health Solutions

    The integration of digital health technologies is becoming increasingly relevant in the hiv diagnostics market. Telehealth services and mobile health applications are facilitating remote consultations and follow-ups, thereby improving access to testing and care. This trend is particularly beneficial for individuals in underserved areas, as it enhances the overall efficiency of healthcare delivery.

    US HIV Diagnostics Market Drivers

    Rising Prevalence of HIV

    The increasing prevalence of HIV in the US is a critical driver for the HIV Diagnostics Market. According to the Centers for Disease Control and Prevention (CDC), approximately 1.2 million people in the US are living with HIV, with around 14% unaware of their infection. This substantial number underscores the necessity for effective diagnostic tools to identify and manage the disease. The growing population of individuals living with HIV necessitates enhanced testing capabilities, thereby propelling the demand for innovative diagnostic solutions. Furthermore, the rising incidence rates among specific demographics, particularly among young adults and marginalized communities, highlight the urgent need for targeted diagnostic strategies. As awareness of HIV continues to grow, the hiv diagnostics market is likely to expand, driven by the need for timely and accurate testing to facilitate early intervention and treatment.

    Emergence of Point-of-Care Testing

    The emergence of point-of-care (POC) testing is transforming the HIV Diagnostics Market by providing rapid and accessible testing options. POC tests allow for immediate results, which is crucial for timely diagnosis and treatment initiation. This shift towards decentralized testing is particularly beneficial in rural and underserved areas where access to traditional laboratory facilities may be limited. The convenience and speed of POC testing can significantly enhance patient engagement and adherence to treatment protocols. According to recent data, the POC testing segment is expected to witness substantial growth, potentially reaching a market value of $1 billion by 2026. This trend indicates a growing recognition of the importance of accessible diagnostic solutions in managing HIV. As healthcare providers increasingly adopt POC technologies, the hiv diagnostics market is likely to expand, driven by the demand for efficient and user-friendly testing methods.

    Government Initiatives and Funding

    Government initiatives and funding play a pivotal role in shaping the HIV Diagnostics Market. The US government has implemented various programs aimed at increasing access to HIV testing and treatment. For instance, the Ryan White HIV/AIDS Program provides essential services to individuals living with HIV, including diagnostic testing. Additionally, the CDC allocates substantial funding for HIV prevention and testing initiatives, which directly impacts the availability and development of diagnostic technologies. In recent years, federal funding for HIV-related programs has seen an increase, reflecting a commitment to combat the epidemic. This financial support not only enhances testing infrastructure but also encourages innovation within the hiv diagnostics market. As government policies continue to evolve, they are likely to foster an environment conducive to the growth of diagnostic solutions, ultimately improving health outcomes for those affected by HIV.

    Growing Demand for Home Testing Kits

    The growing demand for home testing kits is reshaping the HIV Diagnostics Market by offering individuals greater privacy and convenience. As awareness of HIV increases, more people are seeking accessible testing options that can be performed in the comfort of their own homes. Home testing kits provide a discreet alternative to traditional testing methods, which may deter some individuals from seeking necessary care. Recent surveys indicate that nearly 50% of individuals would prefer to use home testing kits for HIV screening. This trend is likely to drive innovation within the hiv diagnostics market, as manufacturers develop user-friendly and reliable home testing solutions. The convenience of home testing may also lead to increased testing rates, ultimately contributing to better public health outcomes. As the market adapts to this growing demand, the availability and variety of home testing kits are expected to expand, further influencing the dynamics of the hiv diagnostics market.

    Advancements in Molecular Diagnostics

    Advancements in molecular diagnostics are significantly influencing the HIV Diagnostics Market. Technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are enhancing the accuracy and sensitivity of HIV testing. These innovations allow for the detection of the virus at lower levels, enabling earlier diagnosis and better monitoring of treatment efficacy. The increasing adoption of molecular diagnostic techniques is expected to drive market growth, as healthcare providers seek more reliable testing options. Recent estimates suggest that the molecular diagnostics segment could account for over 30% of the total hiv diagnostics market by 2027. This shift towards more sophisticated testing methods reflects a broader trend in healthcare towards precision medicine. As molecular diagnostics continue to evolve, they are likely to play a crucial role in the future of the hiv diagnostics market, improving patient outcomes through enhanced testing capabilities.

    Market Segment Insights

    By Test Type: Antibody Tests (Largest) vs. Antigen Tests (Fastest-Growing)

    In the US HIV Diagnostics Market, the distribution of market share among test types reveals a competitive landscape. Antibody tests hold the largest share, widely recognized for their efficacy in detecting HIV antibodies. They have established themselves as the preferred option for many healthcare providers due to their reliability and widespread availability. Conversely, antigen tests are rapidly gaining traction and are becoming preferred due to their ability to detect active infections, providing timely results that are crucial in patient management. Growth trends in the US hiv diagnostics market signal a shift towards more innovative testing methodologies. Antigen tests are emerging as the fastest-growing segment, driven by advancements in technology that enhance product reliability and ease of use. Factors such as increased awareness of HIV testing and a push for more accessible healthcare also contribute significantly to the upward growth trajectory of both antibody and antigen tests, reflecting changing consumer preferences and healthcare policies.

    Antibody Tests (Dominant) vs. Antigen Tests (Emerging)

    Antibody tests continue to dominate the US hiv diagnostics market, owing to their established presence and extensive use in clinical settings. Their primary strength lies in their accuracy and cost-effectiveness, making them a staple in HIV screening programs. On the other hand, antigen tests are the emerging category, characterized by their ability to detect the HIV virus earlier than antibody tests. This feature presents a significant advantage, especially in early detection scenarios. As healthcare systems prioritize rapid and efficient diagnostic solutions, the appeal of antigen tests is growing, supported by innovations that improve their usability in various settings, including home testing.

    By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

    In the US HIV Diagnostics Market, the distribution of market share among the end user segments reveals that hospitals hold the largest share, serving as the primary point for patient diagnosis and management. Conversely, diagnostic laboratories are rapidly gaining ground, supported by advancements in technology and a rising demand for specialized testing options. Home care settings, while an important segment, currently represent a smaller portion of the market compared to hospitals and diagnostic labs. The growth trends in the end user segment are driven by various factors, including increasing awareness of HIV testing, advancements in diagnostic technology, and the shift towards decentralized healthcare. As more individuals seek convenient testing options, home care settings are beginning to emerge as potential growth areas. Diagnostic laboratories are expanding their capabilities to cater to this demand, establishing themselves as key players for the future.

    Hospitals: Dominant vs. Home Care Settings: Emerging

    Hospitals remain the dominant end user in the US hiv diagnostics market, benefiting from comprehensive resources and access to a wide array of diagnostic tools. Their established infrastructure supports the timely and accurate diagnosis of HIV, making them essential in patient care. On the other hand, home care settings are positioned as an emerging segment, driven by a growing need for convenience and privacy in testing. These settings offer patients the ability to undergo testing in their own environment, potentially increasing the overall number of individuals willing to get tested. The trend towards telehealth and home-based care solutions enhances the attractiveness of this emerging segment, indicating a shift in patient preferences.

    By Product Type: Test Kits (Largest) vs. Instruments (Fastest-Growing)

    In the US HIV Diagnostics Market, Test Kits hold the largest share within the product type segment, indicating their widespread preference among healthcare providers and patients for rapid and reliable testing solutions. This segment is favored due to its ease of use, accessibility, and the ability to deliver quick results, which are crucial in managing and controlling HIV transmission effectively. On the other hand, the Instruments segment is emerging as the fastest-growing category, driven by advancements in technology and automation in diagnostic processes. The integration of advanced features in diagnostic instruments enhances precision and efficiency, making them increasingly attractive for clinical laboratories. The push towards more comprehensive testing approaches and real-time monitoring is further fueling demand for sophisticated diagnostic instruments.

    Test Kits: Dominant vs. Instruments: Emerging

    Test Kits are characterized by their user-friendly nature, allowing for self-administration and immediate results, thereby streamlining the testing process. They are particularly dominant in settings where quick diagnosis is essential, such as urgent care centers and during outreach programs. In contrast, Instruments are becoming an emerging force in the market, showcasing innovative technologies that offer enhanced sensitivity and specificity. These devices often accompany laboratory settings where bulk testing is conducted, and errors must be minimized. The distinction between the two highlights a market that values both immediate results and advanced technological capabilities.

    By Technology: Elisa (Largest) vs. Rapid Testing (Fastest-Growing)

    In the US HIV Diagnostics Market, Elisa testing holds the largest share among the various technologies, primarily due to its reliability and established usage in clinical settings. Rapid testing follows, capturing a significant portion of the market thanks to its ability to deliver quick results and facilitate immediate treatment decisions, although its share is smaller compared to Elisa. The Polymerase Chain Reaction (PCR) method, while critical for accurate viral load measurements, remains less common compared to these other two methods due to its higher complexity and cost. The growth trends in this segment are driven by increasing healthcare initiatives aimed at expanding testing access and early diagnosis. Rapid testing is emerging as the fastest-growing segment, bolstered by technological advancements and heightened demand for immediate results. Meanwhile, Elisa technology continues to thrive due to its widespread acceptance and integration in existing healthcare frameworks, ensuring its dominant position for the foreseeable future.

    Technology: Elisa (Dominant) vs. Rapid Testing (Emerging)

    Elisa testing is widely recognized as the dominant technology in the US hiv diagnostics market. It is highly regarded for its accuracy and efficacy, making it a go-to method for confirming HIV infections. The method has a long-standing presence in laboratories, which contributes to its strong market position. In contrast, rapid testing is an emerging technology that is gaining traction due to its user-friendly design and swift results, often available within minutes. This aspect makes rapid testing particularly appealing in urgent care settings and among populations with limited access to healthcare facilities. As the demand for faster diagnostic tools increases, rapid testing is expected to expand its share and relevance within the market.

    Get more detailed insights about US HIV Diagnostics Market

    Key Players and Competitive Insights

    The HIV diagnostics market is characterized by a dynamic competitive landscape, driven by technological advancements, increasing awareness, and the need for rapid testing solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing, which aligns with the growing demand for rapid and accurate diagnostics. Roche Diagnostics (CH) emphasizes partnerships and collaborations to expand its product offerings, while Thermo Fisher Scientific (US) is investing in digital transformation to streamline operations and improve customer engagement. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and strategic partnerships.

    In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger companies leverage their resources to capture significant market share. The collective influence of these key players shapes the market dynamics, fostering an environment where innovation and strategic positioning are paramount.

    In October 2025, Abbott Laboratories (US) announced the launch of a new rapid HIV test that provides results in under 15 minutes, significantly reducing the time required for diagnosis. This strategic move is likely to enhance Abbott's competitive edge by addressing the urgent need for quick testing solutions, particularly in underserved regions. The introduction of this product may also align with public health initiatives aimed at increasing testing rates and improving patient outcomes.

    In September 2025, Roche Diagnostics (CH) expanded its collaboration with a leading telehealth provider to integrate HIV testing into remote healthcare services. This partnership is strategically important as it reflects the growing trend towards telemedicine, allowing Roche to reach a broader patient base and enhance accessibility to HIV diagnostics. By leveraging telehealth, Roche is likely to position itself as a leader in innovative healthcare solutions, catering to the evolving needs of patients and healthcare providers.

    In August 2025, Thermo Fisher Scientific (US) unveiled a new AI-driven analytics platform designed to enhance the accuracy of HIV diagnostics. This platform utilizes machine learning algorithms to analyze test results and provide actionable insights for healthcare professionals. The strategic importance of this development lies in its potential to improve diagnostic accuracy and streamline workflows, thereby enhancing patient care. By integrating AI into its offerings, Thermo Fisher is likely to differentiate itself in a competitive market increasingly focused on technology-driven solutions.

    As of November 2025, current trends in the HIV diagnostics market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly vital, as companies seek to enhance their capabilities and expand their reach. The competitive landscape is shifting from traditional price-based competition to a focus on innovation, technology, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will likely achieve a sustainable competitive advantage in the future.

    Key Companies in the US HIV Diagnostics Market market include

    Industry Developments

    The US HIV Diagnostics Market has witnessed various developments recently, with companies like Abbott Laboratories and Roche Holding focusing on enhancing testing technologies and ensuring broader accessibility. Notably, Abbott Laboratories launched its new HIV test in September 2023, designed to increase diagnosis rates, particularly among underserved populations. In addition, BioRad Laboratories has been working on innovative solutions to improve laboratory testing efficiency.

    The market has experienced significant growth, with valuations of enterprises like Hologic and Quidel Corporation showing robust upward trends due to increased federal funding for HIV testing initiatives. There were no recent mergers or acquisitions reported among key players in the US HIV Diagnostics Market.

    In the last two to three years, significant advancements, such as the FDA's approval of rapid testing devices, have shaped the market dynamics, encouraging competitive innovation among major players like Grifols and Siemens Healthineers. As the government continues to emphasize HIV awareness and testing, the overall landscape remains optimistic, reflecting an ongoing commitment to eradicating the epidemic by improving diagnostic capabilities across the United States.

    Future Outlook

    US HIV Diagnostics Market Future Outlook

    The HIV diagnostics market is projected to grow at 4.05% CAGR from 2024 to 2035, driven by technological advancements, increased awareness, and enhanced testing accessibility.

    New opportunities lie in:

    • Development of mobile testing units for remote areas
    • Integration of AI for rapid diagnostic analysis
    • Expansion of telehealth services for HIV testing consultations

    By 2035, the market is expected to achieve substantial growth, reflecting advancements in diagnostics and increased healthcare access.

    Market Segmentation

    US HIV Diagnostics Market End User Outlook

    • Hospitals
    • Diagnostic Laboratories
    • Home Care Settings

    US HIV Diagnostics Market Test Type Outlook

    • Antibody Tests
    • Antigen Tests
    • Nucleic Acid Tests

    US HIV Diagnostics Market Technology Outlook

    • Elisa
    • Rapid Testing
    • Polymerase Chain Reaction

    US HIV Diagnostics Market Product Type Outlook

    • Tests Kits
    • Instruments
    • Software

    Report Scope

    MARKET SIZE 2024 690.48(USD Million)
    MARKET SIZE 2025 718.44(USD Million)
    MARKET SIZE 2035 1068.59(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 4.05% (2024 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019 - 2024
    Market Forecast Units USD Million
    Key Companies Profiled Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Becton Dickinson and Company (US), Hologic Inc. (US), Cepheid (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US)
    Segments Covered Test Type, End User, Product Type, Technology
    Key Market Opportunities Integration of advanced molecular diagnostics enhances early detection and treatment options in the hiv diagnostics market.
    Key Market Dynamics Technological advancements and regulatory changes drive innovation in the HIV diagnostics market, enhancing testing accuracy and accessibility.
    Countries Covered US

    Leave a Comment

    FAQs

    What is the projected market size of the US HIV Diagnostics Market in 2024?

    The US HIV Diagnostics Market is projected to be valued at 774.2 million USD in 2024.

    What is the expected market size in 2035?

    By 2035, the US HIV Diagnostics Market is expected to reach a valuation of 1249.5 million USD.

    What is the expected CAGR for the US HIV Diagnostics Market from 2025 to 2035?

    The expected CAGR for the US HIV Diagnostics Market from 2025 to 2035 is 4.448%.

    Which test type segment is projected to have the highest market value in 2035?

    The Antibody Tests segment is projected to be valued at 400.0 million USD in 2035.

    What is the expected market value for Nucleic Acid Tests in 2024?

    In 2024, the market value for Nucleic Acid Tests is expected to be 284.2 million USD.

    Who are the major players in the US HIV Diagnostics Market?

    Some of the major players include Abbott Laboratories, Roche Holding, and Hologic.

    What is the projected market value for Antigen Tests in 2035?

    The projected market value for Antigen Tests in 2035 is 400.0 million USD.

    How much is the Antibody Tests segment valued at in 2024?

    The Antibody Tests segment is valued at 250.0 million USD in 2024.

    What challenges are currently faced by the US HIV Diagnostics Market?

    Current challenges include regulatory hurdles and the need for extensive awareness and education.

    What growth opportunities exist within the US HIV Diagnostics Market?

    Growth opportunities are present in technological advancements and increasing demand for rapid and accurate diagnostics.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions